A Pilot Study of Rituximab Neoadjuvant Therapy in Patients With High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 03 May 2019
At a glance
- Drugs Rituximab (Primary)
- Indications Prostate cancer
- Focus Biomarker; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 17 May 2017 Planned End Date changed from 1 Apr 2018 to 1 Apr 2019.
- 17 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.